Recent coverage
Front-page news, podcasts and videos about Andrew
Seattle-area CaaMTech Raises $22M to Develop Novel Tryptamines, Aiming for Human Testing
Seattle-area startup CaaMTech raised $22 million to develop synthesized tryptamine compounds similar to those in psilocybin and LSD, aiming to create defined formulations that maximize desired psychedelic effects and minimize side effects. The company says many of its novel agents are unscheduled in the U.S., and it plans to advance toward human testing amid growing investment and interest in psychedelics for mental-health treatments.
CaaMTech Secures $22 Million Series A Led by Noetic Fund to Push Psychedelic Drug Candidates into Human Trials
CaaMTech raised $22 million in a Series A led by Noetic Fund to advance its analytically pure psychedelic compound library toward human clinical trials, expand its leadership team, and support its cross-disciplinary research program.
Organizations
See all 6-
CaaMTech Founder & CEO 2019–present · current
-
Ebbu Chief Innovations Officer 2017–2018 · past
-
NewMarket Pharmaceuticals Director of Intellectual Property 2011–2013 · past
Education
-
The George Washington University Law School J.D., Patent Law · 2007–2011
-
Cornell University Doctor of Philosophy - PhD, Chemistry · 2001–2006
-
Princeton University Bachelor of Arts, Neuropsychology and Chemistry · 1997–2001
-
Pleasantville High School
Online
Questions about Andrew Chadeayne
Who is Andrew Chadeayne?
Andrew Chadeayne is Founder & CEO at CaaMTech.
Which organizations is Andrew Chadeayne associated with?
On Seattle Flow, Andrew Chadeayne is listed with CaaMTech, Ebbu, NewMarket Pharmaceuticals and 3 more.
Where did Andrew Chadeayne study?
Andrew Chadeayne studied at The George Washington University Law School, Cornell University, Princeton University and 1 more.
Where is Andrew Chadeayne based?
Andrew Chadeayne is based in Issaquah, Washington, United States.